Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954444 · ClinicalTrials.gov registry record · Phase 3
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,105
- Enrollment target
NCT03954444 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 1,105 participants.
The verdict
NCT03954444, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,105 participants
- Enrollment target
Study Summary
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea
Interventions
- DRUG Placebo
- DRUG Oxymetazoline Hydrochloride
- DRUG Rhofade Cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,105 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03954444
The ClinicalTrials.gov registry entry for NCT03954444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03954444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03954444 about?
NCT03954444 is a clinical study titled "A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"". A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of Moderate to Severe Persistent Faci...
What is the current status of trial NCT03954444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,105 participants. The study started on 2019-04-15. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03954444?
The interventions under investigation include: Placebo (DRUG), Oxymetazoline Hydrochloride (DRUG), Rhofade Cream, 1% (DRUG).
Who is sponsoring clinical trial NCT03954444?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.